Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Description

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

Conditions

Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site

Talk to us

Study Overview

On this page

Study Details

Study overview

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Condition
Bladder Carcinoma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with the following cancer types:
  • * Brain cancer
  • * Bladder cancer
  • * Urothelial cancer
  • * Testicular cancer
  • * Skin cancer
  • * Thyroid cancer
  • * Hepatocellular carcinoma
  • * Cholangiocarcinoma
  • * Thymus cancer
  • * Pleural cancer
  • * Cervical cancer
  • * Adrenal cancer
  • * Neuroendocrine tumors
  • * Hematologic cancer
  • * Cancer of Unkown Primary
  • * Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
  • * Patients are ≥ 18 years old at the time of the radiotracer administration.
  • * Patient can provide written informed consent
  • * Patient is able to remain still for duration of imaging procedure (up to one hour)
  • * Patient is pregnant or nursing
  • * Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
  • * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Jeremie Calais, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

2026-07-01